Long non-coding RNA MIAT serves as a biomarker of fragility fracture and promotes fracture healing.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Yu C;Yu C; Chen B; Chen B; Su H; Su H; Yang Y; Yang Y
  • Source:
    Journal of orthopaedic surgery and research [J Orthop Surg Res] 2024 Jun 08; Vol. 19 (1), pp. 343. Date of Electronic Publication: 2024 Jun 08.
  • Publication Type:
    Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101265112 Publication Model: Electronic Cited Medium: Internet ISSN: 1749-799X (Electronic) Linking ISSN: 1749799X NLM ISO Abbreviation: J Orthop Surg Res Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, 2006-
    • Subject Terms:
      RNA, Long Noncoding*/genetics ; Biomarkers*/blood ; Biomarkers*/metabolism ; Fracture Healing*/genetics ; Fracture Healing*/physiology ; Cell Differentiation*/genetics ; Osteoblasts*/metabolism; Humans ; Female ; Aged ; Animals ; Mice ; MicroRNAs/genetics ; Osteoporosis/genetics ; Osteoporosis/metabolism ; Osteogenesis/genetics ; Osteogenesis/physiology ; Middle Aged ; Osteoporotic Fractures/genetics ; Cell Proliferation/genetics ; Up-Regulation
    • Abstract:
      Background: Fragility fracture is common in the elderly. Osteoblast differentiation is essential for bone healing and regeneration. Expression pattern of long non-coding RNA MIAT during fracture healing was examined, and its role in osteoblast differentiation was investigated.
      Methods: 90 women with simple osteoporosis and 90 women with fragility fractures were included. Another 90 age-matched women were set as the control group. mRNA levels were tested using RT-qPCR. Cell viability was detected via CCK-8, and osteoblastic biomarkers, including ALP, OCN, Collagen I, and RUNX2 were tested via ELISA. The downstream miRNAs and genes targeted by MIAT were predicted by bioinformatics analysis, whose functions and pathways were annotated via GO and KEGG analysis.
      Results: Serum MIAT was upregulated in osteoporosis women with high accuracy of diagnostic efficacy. Serum MIAT was even elevated in the fragility fracture group, but decreased in a time manner after operation. MIAT knockdown promoted osteogenic proliferation and differentiation of MC3T3-E1, but the influences were reversed by miR-181a-5p inhibitor. A total of 137 overlapping target genes of miR-181a-5p were predicted based on the miRDB, TargetScan and microT datasets, which were mainly enriched for terms related to signaling pathways regulating pluripotency of stem cells, cellular senescence, and osteoclast differentiation.
      Conclusions: LncRNA MIAT serves as a promising biomarker for osteoporosis, and promotes osteogenic differentiation via targeting miR-181a-5p.
      (© 2024. The Author(s).)
    • References:
      Exp Ther Med. 2020 Dec;20(6):271. (PMID: 33199996)
      Lancet Diabetes Endocrinol. 2017 Nov;5(11):908-923. (PMID: 28689768)
      Mol Med. 2021 Jul 22;27(1):81. (PMID: 34294046)
      Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7232-7246. (PMID: 31539110)
      Arch Osteoporos. 2020 Feb 24;15(1):25. (PMID: 32095943)
      Expert Opin Investig Drugs. 2023 Jul-Dec;32(9):855-865. (PMID: 37740660)
      Br Med Bull. 2022 Jul 9;142(1):34-43. (PMID: 35488320)
      Exp Mol Med. 2019 May 9;51(5):1-8. (PMID: 31073120)
      Oral Dis. 2021 Jul;27(5):1268-1282. (PMID: 32890413)
      Int J Mol Sci. 2021 Sep 30;22(19):. (PMID: 34638983)
      JBJS Rev. 2017 Aug;5(8):e4. (PMID: 28796695)
      Arch Oral Biol. 2015 Feb;60(2):234-41. (PMID: 25463901)
      Eur Radiol Exp. 2021 Oct 19;5(1):47. (PMID: 34664136)
      Gastroenterology. 2018 Feb;154(3):748-750. (PMID: 29337149)
      Br Med Bull. 2008;88(1):147-56. (PMID: 18596049)
      Cell Biol Int. 2017 Jan;41(1):33-41. (PMID: 27797128)
      Mol Biol Rep. 2023 Jan;50(1):517-530. (PMID: 36352177)
      Osteoporos Int. 2022 May;33(5):1125-1136. (PMID: 35034156)
      Curr Osteoporos Rep. 2022 Dec;20(6):469-477. (PMID: 36342642)
      Front Endocrinol (Lausanne). 2018 Oct 04;9:587. (PMID: 30349507)
      Theranostics. 2021 Jul 6;11(16):7995-8007. (PMID: 34335976)
      Aging (Albany NY). 2022 Apr 5;14(7):3143-3154. (PMID: 35381577)
      J Bone Miner Res. 2020 May;35(5):861-868. (PMID: 31914206)
      Br Med Bull. 2011;100:39-57. (PMID: 21429948)
      Br Med Bull. 2020 May 15;133(1):79-94. (PMID: 32219416)
      J Med Life. 2014;7 Spec No. 2:49-53. (PMID: 25870673)
      Br Med Bull. 2021 Jun 10;138(1):58-67. (PMID: 33454750)
      Br Med Bull. 2023 Dec 11;148(1):58-69. (PMID: 37675799)
      Aging (Albany NY). 2023 Feb 3;15(3):734-747. (PMID: 36734882)
      Elife. 2020 Oct 23;9:. (PMID: 33095159)
      Int J Nanomedicine. 2017 May 11;12:3637-3651. (PMID: 28553104)
      Br Med Bull. 2019 Jun 19;130(1):137-147. (PMID: 31066454)
      J Mol Histol. 2022 Apr;53(2):285-296. (PMID: 35286539)
      Bioengineered. 2022 Mar;13(3):6343-6352. (PMID: 35282774)
      Medicina (Kaunas). 2021 Oct 17;57(10):. (PMID: 34684156)
      Br J Cancer. 2017 May 23;116(11):1451-1461. (PMID: 28449010)
      Curr Genomics. 2015 Dec;16(6):441-52. (PMID: 27019619)
      Biomed Pharmacother. 2018 Mar;99:629-637. (PMID: 29625528)
      Sci Rep. 2020 Feb 20;10(1):3078. (PMID: 32080264)
    • Contributed Indexing:
      Keywords: Fracture healing; MC3T3-E1; MIAT/miR-181a-5p; Osteoporosis
    • Accession Number:
      0 (RNA, Long Noncoding)
      0 (Miat long non-coding RNA)
      0 (Biomarkers)
      0 (MicroRNAs)
      0 (MIrn181 microRNA, human)
    • Publication Date:
      Date Created: 20240607 Date Completed: 20240608 Latest Revision: 20240617
    • Publication Date:
      20240617
    • Accession Number:
      PMC11162066
    • Accession Number:
      10.1186/s13018-024-04824-7
    • Accession Number:
      38849896